Activities of Carl SCHLYTER related to 2012/2066(INI)
Shadow reports (1)
REPORT on the protection of public health from endocrine disrupters PDF (191 KB) DOC (126 KB)
Amendments (18)
Amendment 30 #
Motion for a resolution
Recital E
Recital E
E. whereas EU legislation contains nolegal provisions concerning endocrine disrupters, but lacks criteria for determining whether a substance should be regarded as having endocrine-disrupting properties, which undermines proper application of the legal provisions;
Amendment 37 #
Motion for a resolution
Recital G
Recital G
G. whereas the standard data requirements in EU chemicals legislation do not contain any information onare insufficient to adequately identify endocrine-disrupting properties;
Amendment 42 #
Motion for a resolution
Paragraph 1
Paragraph 1
1. Considers, on the basis of an overall assessment of the state of knowledge, that the p on the major adverse and irreversible effects that are cautionary principlesed, likely to be caused and possible to be caused by endocrine disrupters, that there is solid scientific ground not only to requires us as legislators to take measures to reduce human exposure to endocrine disruptors to a minimum, but to do so urgently;
Amendment 54 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Takes the view that the fearedknown, probable and potential effects of endocrine disruptors are so serious that the absence of precise knowledge, including exact knowledge of causal links, should not prevent us from taking measures to protect humans and animals;
Amendment 58 #
Motion for a resolution
Paragraph 2 a (new)
Paragraph 2 a (new)
2 a. Considers that calls for full scientific proof of causality before taking any action in the name of "sound science" are in fact motivated by vested interests to delay any action against endocrine disrupters and have nothing to do with good science as they ignore the complexities and irreducible uncertainties referred to in paragraph D;
Amendment 59 #
Motion for a resolution
Paragraph 3
Paragraph 3
3. Calls, therefore, on the Commission to submit as soon as possible proposals for overarching criteria together with for known, probable and potesnting and information requirements for chemicals on the commercial market, and for EU legislation to make clear what is regarded as a substance with endocrine- disrupting properties; advocates considering the introduction of ‘endocrine disruptor’ as a regulatory hazard class; al endocrine disrupters, and to adapt the testing requirements for chemicals including pesticides and biocides accordingly, to ensure that endocrine disrupters on the commercial market can effectively be identified, so that EU legislation can address them adequately; advocates the introduction of ‘endocrine disruptor’ as a regulatory hazard class, with different categories based on the strength of evidence as also applied for CMR substances;
Amendment 75 #
Motion for a resolution
Paragraph 5
Paragraph 5
5. Takes the view that the criteria for defining endocrine disruptors should be based on criteria for defining ‘adverse effect’ and ‘endocrine mode of action’; considers that both these criteria must be weighed up in parallel in order to carry out a comprehensive assessment; considers that proven effects should be assumed to be harmful as long as there is no scientific data to indicate the opposite, unless the opposite can clearly be shown; considers that hormone-related action should be assumed as soon as interaction with the hormone system can be assumed with reasonable certainty; stresses that any possible combination effects should be taken into consideration;
Amendment 82 #
Motion for a resolution
Paragraph 6 a (new)
Paragraph 6 a (new)
6 a. Strongly disagrees with the attempts to introduce the criterion of 'potency' as a cut-off for the definition of endocrine disrupters, as this would unduly limit the definition of endocrine disrupters, would be scientifically flawed and not coherent with the classification of CMR substances which is based on strength of evidence;
Amendment 86 #
Motion for a resolution
Paragraph 7
Paragraph 7
7. Takes the view that all peer-reviewed scientific studies, including non-GLP studies, should be taken into account, subject to their strengths and weaknesses, in assessing whether a substance does or does not have endocrine- disrupting properties; further considers it important to take account of modern methods and up-to- date research;
Amendment 88 #
Motion for a resolution
Paragraph 8
Paragraph 8
8. Calls on the Commission to introduce in all relevant EU legislation appropriate testing requirements for the identification of substances with endocrine-disrupting properties; considers that the validated and internationally recognised testing methods that have been developed in (for example) the OECD, in EURL ECVAM or under the US EPA Endocrine Disruptor Screening Program must be implemented; notes that the OECD programme of testing methods covers sex hormones and thyroid hormones as well as steroidogenesis; points out, on the other hand, that there are no tests for many other areas of the endocrine system, e.g. insulin and growth hormones; considers that testing methods and guidance documents should be developed so as to take better account of endocrine disruptors, possible low-dose effects and non- monotonic dose-response relationships, in particular with regard to critical windows of exposure during development;
Amendment 100 #
Motion for a resolution
Paragraph 10
Paragraph 10
10. Calls on the Commission, in its review of to revise its EU strategy on endocrine disruptors, to so that it delivers effective protection of human health by placeing greater emphasis on the precautionary principle and work towardsthe need to take preventive action to reducinge human exposure to endocrine disruptors;
Amendment 110 #
Motion for a resolution
Paragraph 10 a (new)
Paragraph 10 a (new)
10 a. Calls on the Commission to put forward a concrete timetable for applying the future criteria and modified testing requirements for endocrine disrupters in relevant legislation, including reviews of the approval of active substances used in pesticides and biocides, and a roadmap with specific actions and targets to reduce exposure to endocrine disrupters;
Amendment 135 #
Motion for a resolution
Paragraph 14
Paragraph 14
14. Stresses that endocrine disruptors should be regarded as substances for which it is not possible to set a limit value atbelow which effects maydo not occur (‘non-threshold’ substances) and that any exposure to such substances may entail a risk; in the context of REACH, endocrine disrupters should therefore fall under Article 60(4) pursuant to which an authorisation may only be granted if it is shown that socio- economic benefits outweigh the risk to human health or the environment arising from the use of the substances and if there are no suitable alternative substances or technologies;
Amendment 137 #
Motion for a resolution
Paragraph 14 a (new)
Paragraph 14 a (new)
14 a. Calls on the Commission to review relevant legislation to ensure that relevant combination effects of endocrine disruptors are effectively addressed;
Amendment 141 #
Motion for a resolution
Paragraph 15
Paragraph 15
15. Calls on the Commission to support targeted research projects on endocrine disruptors, including the development of new testing and analysis methods as well as supporting a paradigm shift towards testing of pathways of toxicity;
Amendment 143 #
Motion for a resolution
Paragraph 15 a (new)
Paragraph 15 a (new)
15 a. Calls on the Commission to establish a financial instrument to finance independent research on endocrine disrupters;
Amendment 153 #
Motion for a resolution
Paragraph 17
Paragraph 17
17. Calls on the Commission to ensure that the criteria for identifying known, probable and potential endocrine disruptors are applied horizontally to all relevant current and future legislation so as to achieve a high level of protection, respectively;
Amendment 157 #
Motion for a resolution
Paragraph 17 a (new)
Paragraph 17 a (new)
17 a. Stresses that while this resolution is limited to addressing the protection of human health from endocrine disrupters, it is equally important to take decisive action on endocrine disrupters to protect wildlife and the environment;